Mechanistic Learning for Combinatorial Strategies With Immuno-oncology Drugs: Can Model-Informed Designs Help Investigators?

被引：12

作者：

Ciccolini, Joseph ^{[1
]}

Barbolosi, Dominique ^{[1
]}

Andre, Nicolas ^{[1
,2
]}

Barlesi, Fabrice ^{[3
]}

Benzekry, Sebastien ^{[4
,5
]}

机构：

[1] Aix Marseille Univ, SMARTc Unit, Ctr Rech Cancerol Marseille, Inserm U1068, Marseille, France

[2] Hop Enfant La Timone, Assistance Publ Hop Marseille, Pediat Hematol & Oncol Dept, Marseille, France

[3] Gustave Roussy Canc Campus, Villejuif, France

[4] CNRS UMR5251, MONC Team, INRIA Bordeaux Sud Ouest, Talence, France

[5] CNRS UMR5251, Inst Math Bordeaux, Talence, France

来源：

JCO PRECISION ONCOLOGY | 2020年 / 4卷

关键词：

ANTI-PD-1; ANTIBODY; CLINICAL-TRIALS; PHASE I/II; TUMOR; IMMUNOTHERAPY; IPILIMUMAB; PREDICTION; EXPOSURE; BENEFITS; EFFICACY;

D O I：

10.1200/PO.19.00381

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：486 / 491

页数：6

共 49 条

[1]

[Anonymous], 2018, J CLIN ONCOL S

[2]

[Anonymous], 2018, J CLIN ONCOL S

[3] Computational oncology - mathematical modelling of drug regimens for precision medicine [J].

Barbolosi, Dominique ;

Ciccolini, Joseph ;

Lacarelle, Bruno ;

Barlesi, Fabrice ;

Andre, Nicolas .

NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (04) :242-254

[4] Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients [J].

Barlesi, Fabrice ;

Imbs, Diane-Charlotte ;

Tomasini, Pascale ;

Greillier, Laurent ;

Galloux, Melissa ;

Testot-Ferry, Albane ;

Garcia, Melanie ;

Elharrar, Xavier ;

Pelletier, Annick ;

Andre, Nicolas ;

Mascaux, Celine ;

Lacarelle, Bruno ;

El Cheikh, Raouf ;

Serre, Raphael ;

Ciccolini, Joseph ;

Barbolosi, Dominique .

ONCOTARGET, 2017, 8 (29) :47161-47166

[5] Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer [J].

Basak, Edwin A. ;

Koolen, Stijn L. W. ;

Hurkmans, Daan P. ;

Schreurs, Marco W. J. ;

Bins, Sander ;

Oomen-de Hoop, Esther ;

Wijkhuijs, Annemarie J. M. ;

den Besten, Ilse ;

Sleijfer, Stefan ;

Debets, Reno ;

van der Veldt, Astrid A. M. ;

Aerts, Joachim G. J., V ;

Mathijssen, Ron H. J. .

EUROPEAN JOURNAL OF CANCER, 2019, 109 :12-20

[6] Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2 [J].

Beinse, Guillaume ;

Tellier, Virgile ;

Charvet, Valentin ;

Deutsch, Eric ;

Borget, Isabelle ;

Massard, Christophe ;

Hollebecque, Antoine ;

Verlingue, Loic .

JCO CLINICAL CANCER INFORMATICS, 2019, 3 :1-10

[7]

Bonate PL, 2011, PHARMACOKINETIC-PHARMACODYNAMIC MODELING AND SIMULATION, SECOND EDITION, P583, DOI 10.1007/978-1-4419-9485-1

[8]

Chatterjee MS, 2017, CPT-PHARMACOMET SYST, V6, P29, DOI 10.1002/psp4.12140

[9] Chemoimmunotherapy: reengineering tumor immunity [J].

Chen, Gang ;

Emens, Leisha A. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (02) :203-216

[10] Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling [J].

Chmielecki, Juliann ;

Foo, Jasmine ;

Oxnard, Geoffrey R. ;

Hutchinson, Katherine ;

Ohashi, Kadoaki ;

Somwar, Romel ;

Wang, Lu ;

Amato, Katherine R. ;

Arcila, Maria ;

Sos, Martin L. ;

Socci, Nicholas D. ;

Viale, Agnes ;

de Stanchina, Elisa ;

Ginsberg, Michelle S. ;

Thomas, Roman K. ;

Kris, Mark G. ;

Inoue, Akira ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Michor, Franziska ;

Pao, William .

SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (90)

← 1 2 3 4 5 →